基于免疫检查点抑制剂（ICI）的肝细胞癌联合疗法中国多学科专家共识（2023 年版）

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Liver Cancer Pub Date : 2024-01-16 DOI:10.1159/000535496

Xiufeng Liu, Yinying Lu, Weiping Zhou, Tao Peng, Jie Zhou, Huaqiang Bi, Feng Xia, Xiaoping Chen

{"title":"基于免疫检查点抑制剂（ICI）的肝细胞癌联合疗法中国多学科专家共识（2023 年版）","authors":"Xiufeng Liu, Yinying Lu, Weiping Zhou, Tao Peng, Jie Zhou, Huaqiang Bi, Feng Xia, Xiaoping Chen","doi":"10.1159/000535496","DOIUrl":null,"url":null,"abstract":"Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC. To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the \"Delphi\" consensus formation method, and finally revised and completed the \"Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)\" on the basis of the 2021 edition. This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":null,"pages":null},"PeriodicalIF":11.6000,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor (ICI)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)\",\"authors\":\"Xiufeng Liu, Yinying Lu, Weiping Zhou, Tao Peng, Jie Zhou, Huaqiang Bi, Feng Xia, Xiaoping Chen\",\"doi\":\"10.1159/000535496\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC. To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the \\\"Delphi\\\" consensus formation method, and finally revised and completed the \\\"Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)\\\" on the basis of the 2021 edition. This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.\",\"PeriodicalId\":18156,\"journal\":{\"name\":\"Liver Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":11.6000,\"publicationDate\":\"2024-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Liver Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000535496\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000535496","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

以免疫检查点抑制剂（ICI）为基础的肝细胞癌（HCC）联合治疗模式在临床研究和实践中取得了显著疗效，已成为治疗无法切除的肝细胞癌的主要手段。为了更好地帮助临床医生合理、有效、安全地使用联合免疫治疗药物和方案，编委会召集该领域多学科专家进行讨论，采用 "德尔菲 "共识形成法，最终在2021年版的基础上修订完成了《基于免疫检查点抑制剂（ICIs）的肝细胞癌联合治疗中国多学科专家共识（2023年版）》。该共识主要针对基于ICIs的联合治疗临床实践的原则和方法，旨在根据最新研究和专家经验总结临床应用建议，为临床医生提供应用指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor (ICI)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)

Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC. To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the "Delphi" consensus formation method, and finally revised and completed the "Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)" on the basis of the 2021 edition. This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Liver Cancer Medicine-Oncology

CiteScore

20.80

自引率

7.20%

发文量

审稿时长

16 weeks

期刊介绍： Liver Cancer is a journal that serves the international community of researchers and clinicians by providing a platform for research results related to the causes, mechanisms, and therapy of liver cancer. It focuses on molecular carcinogenesis, prevention, surveillance, diagnosis, and treatment, including molecular targeted therapy. The journal publishes clinical and translational research in the field of liver cancer in both humans and experimental models. It publishes original and review articles and has an Impact Factor of 13.8. The journal is indexed and abstracted in various platforms including PubMed, PubMed Central, Web of Science, Science Citation Index, Science Citation Index Expanded, Google Scholar, DOAJ, Chemical Abstracts Service, Scopus, Embase, Pathway Studio, and WorldCat.